WAYNE, Pa.--(BUSINESS WIRE)--Encorium Group, Inc. (Nasdaq: ENCO), a leader in the design, development, and management of complex clinical trials and patient registries for many of the world’s leading pharmaceutical and biotechnology companies, announced today the awarding of a Phase 1 contract having a value of approximately $1.2 million. This contract is in support of an innovative approach to the development of a vaccine for the prevention of multiple types of influenza including Seasonal and Pandemic Avian Flu. Services include consulting on clinical trial design and protocol development, project and study site management and monitoring, data management, and biostatistical support. Revenue recognition will begin in the first quarter of 2007 on a proportional performance basis over the life of the contract as services are performed.
